Background: Management of drug-resistant tuberculosis (DR-TB) has improved with the introduction of shorter regimens following the approval of bedaquiline in 2012. Despite its benefits, bedaquiline carries a black box warning due to its potential to prolong the QT interval, raising concerns about cardiotoxicity. This study aimed to evaluate changes in QTcF, determine the prevalence of QT prolon…